NOTE: The prior two installments of this series are found here and here.
The late Dr. Zelenko popularized the treatment of COVID with hydroxychloroquine (HCQ), zinc, and azithromycin (AZM) after getting phenomenal success with it in his patients. When almost 4,000 hospital patients in France were retrospectively analyzed, it was discovered that the combination of HCQ+AZM had been very beneficial:
The hazard ratio (HR) of 0.18 coincides with an efficacy estimate of 0.82, or 82% efficacy against ICU admission or death. The lower bound of the efficacy estimate was 0.73 — a 95% lower bound efficacy of 73% against ICU admission and death. This qualifies HCQ+AZM therapy for meeting the WHO world standard for efficacy.
That standard is a point-estimated 50% efficacy, with a lower bound of 30% efficacy.
In Nov 2021, a study was published using a modification of the Zelenko protocol where there was additional vitamin D and, in one group, even intravenous vitamin C. They found phenomenal results in 237 hospitalized patients, with full recoveries in all but 1 patient, who died:
Of note is that the one patient that did die had a level of active vitamin D which was so low that it does not even support human physiology (i.e., just 6 nmol/L or 2.4 ng/mL). Healthy levels of vitamin D are over 10 times higher than that.
Also of note is that these patients were not healthier than average. Over a third of them had diabetes, over a third had heart disease, and over a third had lung disease — and over 40% of them were heavy smokers. Compared to historic reference, their hospital death rate of (1/236=) 0.4% was significantly low:
In cell D5 is the lower bound hospital death rate for COVID during 2020. In cell E14 is the upper bound hospital death rate for patients taking the modified Zelenko protocol (with vitamin D added, and i.v. vitamin C in one group). Not only is there no crossover, but the difference in boundary values represents 69% efficacy against death.
Reference
[modified Zelenko protocol kept 235 out of 236 hospitalized COVID patients alive] — Ried K, BinJemain T, Sali A. Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial. Cureus. 2021 Nov 25;13(11):e19902. doi: 10.7759/cureus.19902. PMID: 34976511; PMCID: PMC8712288. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712288/
[almost 4,000 patients found to do much better on HCQ+AZM in France] — Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, Honoré S, Gaubert JY, Fournier PE, Tissot-Dupont H, Chabrière E, Stein A, Deharo JC, Fenollar F, Rolain JM, Obadia Y, Jacquier A, La Scola B, Brouqui P, Drancourt M, Parola P, Raoult D; IHU COVID-19 Task force. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 Jul-Aug;36:101791. doi: 10.1016/j.tmaid.2020.101791. Epub 2020 Jun 25. PMID: 32593867; PMCID: PMC7315163. https://pubmed.ncbi.nlm.nih.gov/32593867/
[hospital death rate for COVID in 2020] — Macedo A, Gonçalves N, Febra C. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Ann Epidemiol. 2021 May;57:14-21. doi: 10.1016/j.annepidem.2021.02.012. Epub 2021 Mar 2. PMID: 33662494; PMCID: PMC7920817. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920817/pdf/main.pdf
.
I Wouldn’t Jump To Conclusions
About The Vaccine.
I’d Wait Until They’re All Dead
Just To Be Sure.
.